TABLE 2.
Univariate and multivariate analysis for DFS and OS in patients with early breast cancer (n = 140).
| Univariate | ||||
|---|---|---|---|---|
| – | DFS | OS | ||
| – | HR (95% CI) | p Value | HR (95% CI) | p Value |
| Tumor size (T2-T3 vs T1) | 1.325 (0.733–2.396) | 0.347 | 1.572 (0.731–3.381) | 0.247 |
| Lymph nodes (N3 vs N0-N2) | 2.915 (1.618–5.253) | <0.001** | 3.059 (1.470–6.365) | 0.003* |
| Histology grade (III vs I/II) | 1.808 (0.962–3.400) | 0.066 | 1.237 (0.561–2.726) | 0.598 |
| ER (negative vs positive) | 1.002 (0.546–1.838) | 0.995 | 1.130 (0.533–2.393) | 0.750 |
| PR (negative vs positive) | 1.229 (0.680–2.222) | 0.496 | 1.802 (0.869–3.738) | 0.113 |
| ER/PR (negative vs at least one positive) | 1.206 (0.635–2.292) | 0.568 | 1.629 (0.756–3.508) | 0.213 |
| Her2 (positive vs negative) | 1.391 (0.648–2.982) | 0.568 | 1.334 (0.509–3.497) | 0.558 |
| miR-10b (low vs high) | 2.134 (1.163–3.916) | 0.014* | 1.994 (0.925–4.297) | 0.078 |
| miR-19a (low vs high) | 1.224 (0.686–2.184) | 0.494 | 1.522 (0.727–3.188) | 0.265 |
| miR-20a (low vs high) | 1.013 (0.568–1.806) | 0.966 | 1.138 (0.549–2.359) | 0.728 |
| miR-126 (low vs high) | 1.696 (0.943–3.052) | 0.078 | 2.152 (1.000–4.632) | 0.044* |
| miR-155 (low vs high) | 1.708 (0.949–3.074) | 0.074 | 2.111 (0.981–4.542) | 0.056 |
| Multivariate | ||||
| Lymph nodes (N3 vs N0-N2) | 2.538 (1.396–4.614) | 0.002* | 3.537 (1.685–7.426) | 0.001* |
| miR-10b (low vs high) | 1.943 (1.055–3.581) | 0.033* | – | – |
| miR-126 (low vs high) | – | – | 2.558 (1.177–5.560) | 0.018* |
DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence intervals; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; * p < 0.05, **p < 0.001.